AEON Biopharma Phase 2 chronic migraine study misses primary and secondary endpoints

AEON Biopharma, Inc.

Phase 2 chronic migraine interim analysis did not achieve primary or secondary endpoints.
End-of-Phase 2 meeting with FDA for episodic migraine resulted in preliminary alignment on Phase 3 design.
Completed $15M private placement with Daewoong; second installment received April 2024.
Seongsoo (Shawn) Park appointed to Board of Directors as Daewoong's representative.
Company evaluating next-steps across late-stage clinical pipeline for ABP-450.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AEON Biopharma, Inc. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the fiscal quarter ended March 31, 2024.

View on SEC.gov

1428 earnings releases filed in the last 30 days. Browse all earnings releases →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-24-000062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.